search
Back to results

Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients

Primary Purpose

Obsessive-Compulsive Disorder, Anxiety Disorders, Mental Disorders

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Fluoxetine
Sertraline
Paroxetine
Citalopram
Fluvoxamine
Exposure and Response Prevention
Sponsored by
Shanghai Mental Health Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obsessive-Compulsive Disorder focused on measuring Cognitive Behavior Therapy, Exposure and Response/Ritual Prevention, Selective Serotonin Reuptake Inhibitors, Psychotherapy, Pharmacotherapy, Citalopram, Fluoxetine, Paroxetine, Sertraline, Fluvoxamine, fMRI, Stop Signal Task

Eligibility Criteria

16 Years - 65 Years (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Having been diagnosed with primary OCD as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-) criteria;Cleaning or checking as primary OCD symptoms
  • Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of ≥ 16
  • Never receiving adequate treatment or stop receiving treatment for at least 8 weeks
  • Having an education degree of high school or above
  • Accepting to participate in the study

Exclusion Criteria:

  • Having significant medical illnesses that would interfere with the conduct of the study
  • Clinically significant abnormal laboratory finding
  • Having comorbid psychiatric conditions according to the criteria set forth in the DSM-IV(administered by the Mini-International Neuropsychiatric Interview (MINI))
  • The current OCD symptoms are too severe that the patient cannot finish the evaluation or receive the ERP
  • Being currently at risk for suicide
  • Being pregnant or having the intention to be pregnant before the end of the study
  • A history of having inadequate response to adequate SSRIs or CBT treatment
  • Subjects who are unable to undergo the MRI

Sites / Locations

  • Shanghai Mental Health Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Selective Serotonin Reuptake Inhibitor

Exposure and Response Prevention

Arm Description

In this group,routine treatment strategies will be used for patients. Any one of the SSRIs including fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine ,which are approved in the treatment of OCD by SFDA, may be used for patients who are randomized to this treatment arm. The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.

Exposure and Response Prevention Structured protocol described by Foa et al., 2012 Patients will attend eight 1-h sessions,once a week. Benzodiazepine will be used when necessary.

Outcomes

Primary Outcome Measures

The change of Yale-Brown Obsessive-Compulsive Scale score
Patients were assessed at 0 week(w), 2w, 4w, 8w, 10w, 12w, 16w(0 month), 6 month

Secondary Outcome Measures

The change of Beck Depression Inventory(BDI) score
Patients were assessed at 0 week(w), 2w, 4w, 8w, 10w, 12w, 16w(0 month), 6 month
The change of Beck Anxiety Inventory(BAI) score
Patients were assessed at 0 week(w), 2w, 4w, 8w, 10w, 12w, 16w(0 month), 6 month
The change of Stress Perceived Questionnaire (PSS-10) score
Patients were assessed at 0 week(w),16w(0 month), 6 month
The change of Behavioral Inhibition/Behavioral Activation System Scales score
Patients were assessed at 0 week(w), 16w(0 month), 6 month
The change of Barratt Impulsiveness Scale 11 (BIS-11) score
Patients were assessed at 0 week(w), 16w(0 month), 6 month
The change of Obsessive Beliefs Questionnaire-44(OBQ-44) score
Patients were assessed at 0 week(w), 16w(0 month), 6 month
The NEO-Five Factor Inventory-Revised (NEO-FFI-R)
Patients were assessed at 0 week(w),
The Early Trauma Inventory Self Report-Short Form(ETISR-SF)
Patients were assessed at 0 week(w)

Full Information

First Posted
December 15, 2013
Last Updated
September 7, 2022
Sponsor
Shanghai Mental Health Center
Collaborators
Shanghai Municipal Science and Technology Commission, Shanghai Jiao Tong University School of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT02022709
Brief Title
Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
Official Title
Efficacy of Exposure and Response Prevention(ERP) and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
November 18, 2017 (Actual)
Study Completion Date
March 13, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shanghai Mental Health Center
Collaborators
Shanghai Municipal Science and Technology Commission, Shanghai Jiao Tong University School of Medicine

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the efficiency of SSRIs(Selective Serotonin Reuptake Inhibitor) ,ERP(Exposure and Response Prevention) and the combination of the two therapies for OCD(Obsessive-Compulsive Disorder) patients ,at the same time, to find out the biological or psychological predictors of treatment response in Chinese population.
Detailed Description
Although Selective Serotonin Reuptake Inhibitors(SSRIs) and Cognitive Behavior Therapy (CBT) including Exposure and Response Prevention(ERP) are two kinds of the first line treatments for OCD(Obsessive-Compulsive Disorder) according to APA(American Psychological Association)guideline. Both of the treatments are effective, but few research has been done to find out who are more responsive to one treatment than the other. The aim of our research is to evaluate the efficiency of SSRIs ,ERP and the combination of the two therapies for OCD patients ,at the same time, to find out the biological and psychological predictors of treatment response in Chinese population. This is a randomized, single-blind, cross-over design study.Approximately 60 patients will be randomized to SSRIs or ERP group. Neuropsychological assessment and fMRI(Functional Magnetic Resonance Imaging) will be performed at baseline,during the treatment and at the end of the study. The research has two period. In the first period(before week 8) ,the patients will have monotherapy. In the second period(after week 8), rates of improvement based on the YBOCS(Yale-Brown Obsessive Compulsive Scale) scores will be assessed. The patient will be considered responsive to treatment when he or she has a reduction in YBOCS score ≥ 35% of the score at the baseline.If the patient is responsive to the treatment that he or she has received at the first 8 weeks,he or she will continue to follow the previous treatment strategy.If not,the patient will have a combination of SSRIs and ERP treatment for another 8 weeks. The follow-up period will last up to 6 months.The result of the study will improve our knowledge about the efficacy of the two first line treatments .Also,it will help us to find out the predictors of the outcome of the two different kinds of treatments.Strategy of clinical treatment of OCD will be more individualized in the future.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obsessive-Compulsive Disorder, Anxiety Disorders, Mental Disorders
Keywords
Cognitive Behavior Therapy, Exposure and Response/Ritual Prevention, Selective Serotonin Reuptake Inhibitors, Psychotherapy, Pharmacotherapy, Citalopram, Fluoxetine, Paroxetine, Sertraline, Fluvoxamine, fMRI, Stop Signal Task

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
78 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Selective Serotonin Reuptake Inhibitor
Arm Type
Active Comparator
Arm Description
In this group,routine treatment strategies will be used for patients. Any one of the SSRIs including fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine ,which are approved in the treatment of OCD by SFDA, may be used for patients who are randomized to this treatment arm. The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
Arm Title
Exposure and Response Prevention
Arm Type
Active Comparator
Arm Description
Exposure and Response Prevention Structured protocol described by Foa et al., 2012 Patients will attend eight 1-h sessions,once a week. Benzodiazepine will be used when necessary.
Intervention Type
Drug
Intervention Name(s)
Fluoxetine
Other Intervention Name(s)
Prozac
Intervention Description
The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
Intervention Type
Drug
Intervention Name(s)
Sertraline
Other Intervention Name(s)
Zoloft
Intervention Description
The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
Intervention Type
Drug
Intervention Name(s)
Paroxetine
Other Intervention Name(s)
Seroxat
Intervention Description
The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
Intervention Type
Drug
Intervention Name(s)
Citalopram
Other Intervention Name(s)
Cipramil
Intervention Description
The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
Intervention Type
Drug
Intervention Name(s)
Fluvoxamine
Other Intervention Name(s)
Luvox
Intervention Description
The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
Intervention Type
Behavioral
Intervention Name(s)
Exposure and Response Prevention
Other Intervention Name(s)
Exposure and Rituals Prevention
Intervention Description
8 exposure and response prevention (ERP) sessions,once a week
Primary Outcome Measure Information:
Title
The change of Yale-Brown Obsessive-Compulsive Scale score
Description
Patients were assessed at 0 week(w), 2w, 4w, 8w, 10w, 12w, 16w(0 month), 6 month
Time Frame
from baseline to month 6
Secondary Outcome Measure Information:
Title
The change of Beck Depression Inventory(BDI) score
Description
Patients were assessed at 0 week(w), 2w, 4w, 8w, 10w, 12w, 16w(0 month), 6 month
Time Frame
from baseline to month 6
Title
The change of Beck Anxiety Inventory(BAI) score
Description
Patients were assessed at 0 week(w), 2w, 4w, 8w, 10w, 12w, 16w(0 month), 6 month
Time Frame
from baseline to month 6
Title
The change of Stress Perceived Questionnaire (PSS-10) score
Description
Patients were assessed at 0 week(w),16w(0 month), 6 month
Time Frame
from baseline to month 6
Title
The change of Behavioral Inhibition/Behavioral Activation System Scales score
Description
Patients were assessed at 0 week(w), 16w(0 month), 6 month
Time Frame
from baseline to month 6
Title
The change of Barratt Impulsiveness Scale 11 (BIS-11) score
Description
Patients were assessed at 0 week(w), 16w(0 month), 6 month
Time Frame
from baseline to month 6
Title
The change of Obsessive Beliefs Questionnaire-44(OBQ-44) score
Description
Patients were assessed at 0 week(w), 16w(0 month), 6 month
Time Frame
from baseline to month 6
Title
The NEO-Five Factor Inventory-Revised (NEO-FFI-R)
Description
Patients were assessed at 0 week(w),
Time Frame
at baseline
Title
The Early Trauma Inventory Self Report-Short Form(ETISR-SF)
Description
Patients were assessed at 0 week(w)
Time Frame
at baseline
Other Pre-specified Outcome Measures:
Title
Stop Signal Task (SST)
Description
a measure of behavioral response inhibition
Time Frame
from baseline to month 6
Title
fMRI(Functional Magnetic Resonance Imaging) - stop signal task
Description
a measure of behavioral response inhibition
Time Frame
from baseline to month 6
Title
C Reaction Protein(CRP)
Description
for safety considerations
Time Frame
from baseline to month 6
Title
Complete Blood Count
Description
for safety considerations
Time Frame
from baseline to month 6
Title
Liver and Kidney Function
Description
for safety considerations
Time Frame
from baseline to month 6
Title
Resting State Functional Magnetic Resonance Imaging
Description
to quantify brain network
Time Frame
from baseline to month 6

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Having been diagnosed with primary OCD as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-) criteria;Cleaning or checking as primary OCD symptoms Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of ≥ 16 Never receiving adequate treatment or stop receiving treatment for at least 8 weeks Having an education degree of high school or above Accepting to participate in the study Exclusion Criteria: Having significant medical illnesses that would interfere with the conduct of the study Clinically significant abnormal laboratory finding Having comorbid psychiatric conditions according to the criteria set forth in the DSM-IV(administered by the Mini-International Neuropsychiatric Interview (MINI)) The current OCD symptoms are too severe that the patient cannot finish the evaluation or receive the ERP Being currently at risk for suicide Being pregnant or having the intention to be pregnant before the end of the study A history of having inadequate response to adequate SSRIs or CBT treatment Subjects who are unable to undergo the MRI
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhen Wang, Ph.D, M.D
Organizational Affiliation
Shanghai Mental Health Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shanghai Mental Health Center
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200030
Country
China

12. IPD Sharing Statement

Learn more about this trial

Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients

We'll reach out to this number within 24 hrs